Glaxo Joins Lawsuit Against Abbott Over Price of Norvir
November 12, 2007
GlaxoSmithKline recently joined a lawsuit against Abbott Laboratories over the price of Abbott's antiretroviral drug Norvir, the Wall Street Journal reports. In the suit filed in U.S. District Court in Oakland, Calif., GSK alleges that Abbott "schemed to remove ... one of the critical components" of an antiretroviral drug combination in 2003 by increasing the price of Norvir, which has been used in combination with GSK's antiretroviral Lexiva (Carreyrou, Wall Street Journal, 11/9).
Previously undisclosed documents and e-mails reviewed by the Journal indicate that executives at Abbott attempted to diminish the attraction of Norvir by increasing the price of the drug. According to the documents and e-mails, Abbott in the fall of 2003 became concerned about new competition to its antiretroviral Kaletra, and the company's executives began discussing ways to decrease the popularity of Norvir as a way to force HIV-positive people to stop using rival drugs and turn to Kaletra.
Abbott has said that it did not increase the price of Norvir to promote Kaletra and that the increase did not affect other drug companies. According to Abbott, the price increase was intended to better show Norvir's medical value (Kaiser Daily HIV/AIDS Report, 10/30). Melissa Brotz, a spokesperson for Abbott, called GSK's suit "frivolous" and "completely without merit" (Wall Street Journal, 11/9).
Seattle Post-Intelligencer Examines Reactions of People Who Participated in Merck's Canceled HIV Vaccine Trial
European Parliament Members Launch Facebook Campaign to Reduce Tax Rate on Condoms to Curb HIV in E.U.
This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.